In vivo measurement of cell proliferation in canine brain tumor using C-11-labeled FMAU and PET

被引:24
作者
Conti, Peter S. [1 ]
Bading, James R. [1 ]
Mouton, Peter P. [2 ]
Links, Jonathan M. [3 ]
Alauddin, Mian M. [1 ]
Fissekis, John D. [1 ]
Ravert, Hayden T. [3 ]
Hilton, John [3 ]
Wong, Dean F. [3 ]
Anderson, James H. [3 ]
机构
[1] Univ So Calif, PET Imaging Sci Ctr, Dept Radiol, Los Angeles, CA 90033 USA
[2] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21218 USA
[3] Johns Hopkins Med Inst, Dept Radiol & Radiol Sci, Baltimore, MD 21218 USA
关键词
D O I
10.1016/j.nucmedbio.2007.09.003
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: Noncatabolized thymidine analogs are being developed for use in imaging DNA synthesis. We sought to relate a labeling index measured by immunohistochemical staining bromodeoxyuridine (BUdR) technique to the uptake of C-11 2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (FMAU) measured with positron emission tomography (PET) in a brain tumor model. Methods: Adult beagles (n=8) with implanted brain tumors received [C-11]FMAU and dynamic imaging with arterial sampling. Six dogs were then infused with BUdR (200 mg/m(2)) and sacrificed. Tumor time-activity curves (TACs) obtained from computed-tomography-defined regions of interest were corrected for partial volume effects and crosstalk from brain tissue. Tissue was analyzed for the percentage of tumor volume occupied by viable cells and by viable cells in S-phase as identified by BUR staining. PET/[C-11]FMAU and BUR were compared by linear regression analysis and analysis of variance, as well as by a nonparametric rank correlation test. Results: Tumor standardized uptake values (SUVs) and tumor-to-contralateral-brain uptake ratios at 50 min were 1.6+/-0.4 and 5.5+/-1.2 (n=8; mean+/-S.E.M.), respectively. No C-11-labeled metabolites were observed in the blood through 60 min. Tumor TACs were well described with a three-compartment/four-parameter model (k(4)=0) and by Patlak analysis. Parametric statistical analysis showed that FMAU clearance from plasma into tumor Compartment 3 (K-FMAU) was significantly correlated with S-phase percent volume (P=.03), while tumor SUV was significantly correlated with both S-phase percent volume and cell percent volume (P=.02 and .03, respectively). Patlak slope, KFMAU and tumor SUV were equivalent with regard to rank correlation analysis, which showed that tumor uptake and trapping of FMAU were correlated with the volume density of dividing cells (P=.0003) rather than nondividing cells (P=.3). Conclusions: Trapping of [C-11]FMAU correlated with tumor growth rate, as measured by direct tissue analysis with BUR in a canine brain tumor model, suggesting that [C-11]FMAU is useful for the imaging of cell proliferation in cancers. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:131 / 141
页数:11
相关论文
共 41 条
[1]   NEW LOOK AT STATISTICAL-MODEL IDENTIFICATION [J].
AKAIKE, H .
IEEE TRANSACTIONS ON AUTOMATIC CONTROL, 1974, AC19 (06) :716-723
[2]   Synthesis of [18F]-labeled 2′-deoxy-2′-fluoro-5-methyl-1-β-D-arabinofuranosyluracil ([18F]-FMAU) [J].
Alauddin, MM ;
Conti, PS ;
Fissekis, JD .
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2002, 45 (07) :583-590
[3]   MULTIMODALITY CORRELATIVE STUDY OF CANINE BRAIN-TUMORS - PROTON MAGNETIC-RESONANCE SPECTROSCOPY - POSITRON EMISSION TOMOGRAPHY, AND HISTOLOGY [J].
ANDERSON, JH ;
STRANDBERG, JD ;
WONG, DF ;
CONTI, PS ;
BARKER, PB ;
BLACKBAND, SJ ;
HILTON, J ;
NATARAJAN, TK ;
DANNALS, RF ;
SAMPHILIPO, MA ;
MAGEE, CA ;
BURCKHARDT, DD .
INVESTIGATIVE RADIOLOGY, 1994, 29 (06) :597-605
[4]   Pharmacokinetics of the thymidine analog 2′-fluoro-5-[14C]-methyl-1-β-D-arabinofuranosyluracil ([14C]FMAU) in rat prostate tumor cells [J].
Bading, JR ;
Shahinian, AH ;
Bathija, P ;
Conti, PS .
NUCLEAR MEDICINE AND BIOLOGY, 2000, 27 (04) :361-368
[5]   Pharmacokinetics of the thymidine analog 2′-fluoro-5-methyl-1-β-D-arabinofuranosyluracil (FMAU) in tumor-bearing rats [J].
Bading, JR ;
Shahinian, AH ;
Vail, A ;
Bathija, P ;
Koszalka, GW ;
Koda, RT ;
Alauddin, MM ;
Fissekis, JD ;
Conti, PS .
NUCLEAR MEDICINE AND BIOLOGY, 2004, 31 (04) :407-418
[6]  
Barthel H, 2003, CANCER RES, V63, P3791
[7]   Positron emission tomography in patients with breast cancer using 18F-3′-deoxy-3′-fluoro-L-thymidine (18F-FLT) -: a pilot study [J].
Been, LB ;
Elsinga, PH ;
de Vries, J ;
Cobben, DCP ;
Jager, PL ;
Hoekstra, HJ ;
Suurmeijer, AJH .
EJSO, 2006, 32 (01) :39-43
[8]   Clinical relevance of imaging proliferative activity in lung nodules [J].
Buck, AK ;
Hetzel, M ;
Schirrmeister, H ;
Halter, G ;
Möller, P ;
Kratochwil, C ;
Wahl, A ;
Glatting, G ;
Mottaghy, FM ;
Mattfeldt, T ;
Neumaier, B ;
Reske, SN .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (05) :525-533
[9]  
BUCK AK, 2002, CANCER RES, V62, P2681
[10]   Molecular Imaging of proliferation in malignant lymphoma [J].
Buck, Andreas K. ;
Bommer, Martin ;
Stilgenbauer, Stephan ;
Juweid, Malik ;
Glatting, Gerhard ;
Schirrmeister, Holger ;
Mattfeldt, Torsten ;
Tepsic, Djurdja ;
Bunjes, Donald ;
Mottaghy, Felix M. ;
Krause, Bernd J. ;
Neumaier, Bernd ;
Doehner, Hartmut ;
Moeller, Peter ;
Reske, Sven N. .
CANCER RESEARCH, 2006, 66 (22) :11055-11061